Elutia Inc. (NasdaqCM: ELUT)
Health Care · Biotechnology · US
$1.01
+6.22% today · -60.2% 1Y
Elutia Inc. (NasdaqCM: ELUT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $42.11M and employs 26 people.
Over the last twelve months the share price has lost 60.2%, trading between 0.50 and 2.50.
Tweenvest scores Elutia Inc. across four factors: quality 33/100, value 38/100, growth 0/100. Its strongest factor is value.
ELUT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $42.11M
- Revenue (TTM)
- $12.14M
- P/E
- —
- EPS
- 1.01
- Dividend yield
- —
- Beta (5Y)
- 0.88
- 52-week high
- $2.50
- 52-week low
- $0.50
- Avg volume (3M)
- —
- Shares outstanding
- 44.29M
- Employees
- 26
- Next earnings
- —
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
- ISIN
- US05479K1060
- Founded
- 2015
- Listed since
- Oct 7, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.